Journal of Arrhythmia
Online ISSN : 1883-2148
Print ISSN : 1880-4276
Volume 22, Issue 1
Displaying 1-9 of 9 articles from this issue
Editorial
Review Articles
  • Hrayr S Karagueuzian, Peng-Sheng Chen, William J Mandel
    2006 Volume 22 Issue 1 Pages 4-18
    Published: January 25, 2006
    Released on J-STAGE: February 19, 2009
    JOURNAL FREE ACCESS
    Download PDF (899K)
  • Stephen Minor, Toshio Akiyama
    2006 Volume 22 Issue 1 Pages 19-30
    Published: January 25, 2006
    Released on J-STAGE: February 19, 2009
    JOURNAL FREE ACCESS
    The management of malignant ventricular arrhythmias will become gradually more important as life expectancy continues to increase. The incidence of sudden cardiac death and overall cardiac mortality is more pronounced in the elderly mainly as a reflection of the higher prevalence of ischemic heart disease. With the exception of beta-blocker therapy, antiarrhythmic drug therapy has not proven to be effective in the prevention of sudden cardiac death. Implantable cardioverter-defibrillator therapy has been shown to reduce both overall mortality and arrhythmic death when following current guidelines for implantation and appears to be applicable to any age group when sensible patient selection is implemented. The greater efficacy of this therapy relative to antiarrhythmic therapies supports its expanded use in the elderly population. Such therapy has a similar cost-effectiveness to other accepted interventions and does not appear to be associated with reduced quality of life or age-specific complications. The clinical approach to elderly patients at risk of sudden death from ventricular arrhythmias will continue to evolve as new technologies are developed, but the future of ventricular arrhythmia treatment in the elderly will likely emphasize an increasing utilization of both implantable cardioverter-defibrillator and beta-blocker therapies.
    Download PDF (110K)
Original Articles
  • Akira Sawa, Akihiko Shimizu, Takeshi Ueyama, Yasuhiro Yoshiga, Shinsuk ...
    2006 Volume 22 Issue 1 Pages 31-36
    Published: January 25, 2006
    Released on J-STAGE: February 19, 2009
    JOURNAL FREE ACCESS
    Objective: Conduction velocity around the tricuspid valve annulus (TA) during typical atrial flutter (AFL) has been shown to be slowest in the inferior vena cava-tricuspid valve (IVC-TV) isthmus when compared to the septal or free wall segments of the TA. We investigated the conduction velocity in IVC-TV isthmus, dividing into three areas. Methods: We evaluated conduction velocity around the TA during typical AFL in 10 patients, using an electro-anatomic mapping system (CARTOTM). Conduction velocity was calculated at six areas around the TA including the septal wall, upper wall, lateral wall, and isthmus wall, which was further divided into three areas, lateral isthmus, mid isthmus, and septal isthmus. Results: Conduction velocity around the TA during typical AFL was slowest in the IVC-TV isthmus. Further, conduction velocities (m/sec) in the mid isthmus (0.44±0.17) and septal isthmus (0.45±0.22) were significantly slower (p<0.05) than that in the upper wall (0.67±0.26). Conclusions: The relatively slower conduction in IVC-TV isthmus resulted from the relatively slower conduction in the area from mid to septal isthmus.
    Download PDF (243K)
  • Takashi Komatsu, Yoshihiro Satou, Hideaki Tachibana, Motoyuki Nakamura ...
    2006 Volume 22 Issue 1 Pages 37-43
    Published: January 25, 2006
    Released on J-STAGE: February 19, 2009
    JOURNAL FREE ACCESS
    This study sought to evaluate the efficacy of long-term flecainide therapy in maintaining sinus rhythms in patients with paroxysmal atrial fibrillation (AF) based on time of onset. Flecainide (150 mg/day) was administered as an antiarrhythmic drug to a total of 70 patients (54 men and 16 women: mean age 65±10 years) after sinus rhythm was restored spontaneously or by electrical and/or pharmacological cardioversion. Paroxysmal AF was divided into three categories based on time of onset: diurnal type (N=11), nocturnal type (N=13), and mixed type (N=46). The mean follow-up period was 37.7±17.7 months. The duration of sinus rhythm maintenance in patients with diurnal and nocturnal paroxysmal AF was 32.4±10.4 months and 20.8±8.3 months, respectively; the duration of sinus rhythm maintenance in those with mixed paroxysmal AF was only 7.2±2.1 months. Significant differences were observed in duration between diurnal and mixed cases (mean±S.E., P<0.05). Actuarial recurrence-free rates at 1, 3, 6, 9 and 12 months were 90.9%, 63.6%, 63.6%, 54.5%, and 54.5%, respectively, for diurnal cases; 84.6%, 76.9%, 53.8%, 38.5%, and 30.8%, respectively, for nocturnal cases; and 58.7%, 39.1%, 28.3%, 21.7%, and 15.2% respectively, for mixed cases. Significant differences in rates at 12 months were observed between diurnal and mixed cases (P<0.05). These results suggest that flecainide is highly effective in preventing AF recurrence in patients with diurnal paroxysmal AF.
    Download PDF (84K)
Short Report
Case Reports
feedback
Top